Interested in the Genedrive share price? Read this first!

first_imgInterested in the Genedrive share price? Read this first! Rupert Hargreaves | Thursday, 22nd October, 2020 | More on: GDR The high-calibre small-cap stock flying under the City’s radar Enter Your Email Address The Genedrive (LSE: GDR) share price has been on a rollercoaster ride this year. The stock was trading at around 9p a share in March but then leapt to more than 200p in early May. The excitement started to build around the company due to its existing technology, which could identify pathogens relatively quickly. This technology, investors speculated, could help revolutionise the testing process for Covid-19. The organisation believed it could cut delays processing lab samples.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Unfortunately, the company’s progress has been slower than many investors may have projected. The practicalities of getting accurate products to market have hampered the business.Consequently, these delays hurt investor sentiment towards the Genedrive share price. The stock has fallen as a result, currently changing hands at just over 111p, down around 50% from that May high. Steady progress Despite the slow progress, Genedrive is pushing forward. Following the CE marking of the Genedrive 96 SARS-CoV-2 kit at the end of May, management has been working to gain approval from regulators around the world to sell the product in different markets.In the United States, Emergency Use Authorisation (EUA) has been applied for and remains under consideration by the FDA. Meanwhile, the approval process in Africa and India is well underway. The South African Health Products Regulatory Authority also approved the product at the end of September. The firm has also signed an agreement with Beckman Coulter Life Sciences to combine the Genedrive 96 SARS Cov 2 testing kit with the Biomek i7 automated work station. And on top of all of the above, Genedrive is working on a new Point-of-Care (POC) system for Covid-19. This product could produce results in approximately 15 minutes. Unlike many other early-stage healthcare companies, the business already has revenue commitments. Its latest trading update noted the firm had £1m of purchase commitments for the Genedrive 96 SARS-CoV-2 kit. Unfortunately, the company also noted it needs regulatory approval before these orders can be filled. Genedrive share price investment potential Still, from an investment perspective, I think the Genedrive share price looks attractive. One of the most common reasons why early-stage healthcare companies fail is lack of funds. That’s not something investors here need to be worried about right now.At the end of June, Genedrive had £8.2m of cash on the balance sheet. I think that could be enough to sustain the business for at least two years. The company should have reached the revenue stage by that point. From there on, the sky could be the limit for Genedrive. As such, while the Genedrive share price has fallen in recent months, I think the firm’s fundamentals look much stronger today than they were at the beginning of the year. If the company’s testing products are approved around the world, the revenue opportunity could be substantial. Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before! See all posts by Rupert Hargreaves Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee.center_img Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Our 6 ‘Best Buys Now’ Shares Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge! Simply click below to discover how you can take advantage of this. I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement. Image source: Getty Images last_img read more


first_imgA funeral mass was held June 11 at Our Lady of Grace Church for Audrey Jones Calligy, 90, of Hoboken. She died June 6. Born in Union City, Audrey spent 87 years living in Hoboken. In 1953, she married Thomas P. Calligy and by 1970, they were the parents of 10 children. Audrey graduated from Seton Hall University and received her Master’s Degree from St. Peter’s College. In 1975, just as her youngest child was starting kindergarten, Audrey was called in as a short-term substitute teacher in Our Lady of Grace School. However, she continued teaching there for the next 20 years. Despite the demands of raising a large family, Audrey always found time to volunteer. Her many contributions to the Hoboken community and Our Lady of Grace Church include teaching CCD classes, collecting baby items for layette donations, distributing food baskets at Thanksgiving, serving as a Eucharistic Minister, volunteering at bingo games, serving as a member and president of the Mothers’ Guild and working with the National Council of Catholic Women, where she also served as president.Audrey is survived by her ten children: John, Mary, Jane, Nancy, Gerard, Carol, Eileen, Brian, Cathleen, Pat and spouses OckKyung Lee, Gregory Stewart, Lisa DeMarco, Richard Carbonaro, Thomas Foley, Catherine Calligy, Jerard Gonzalez, and Elaine Calligy. She is also survived by her sister-in-law Geraldine Calligy. Audrey was the proud grandmother of 22 and great-grandmother of 5. A special thank you to Aurelia for her extraordinary care and kindness. Audrey was predeceased by Thomas P. Calligy, her husband of 60 years, her parents, Annabelle and John Jones, her brother John Jones, Jr., and her sister Jacquelyn as well as her sons-in-law Donald Carrie and Roger Schechter. at 10:45am. Interment to follow at Holy Name Cemetery, Jersey City.Services arranged by the the Earl F. Bosworth Funeral Home, Hoboken.last_img read more